{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:08:00Z","timestamp":1769828880371,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>About 20% to 40% of patients with non-small cell lung cancer (NSCLC) will develop brain metastases during the natural course of their disease. The prognosis for such patients is very poor with limited survival. In addition to the standard whole brain radiation therapy (WBRT), some studies have shown that chemotherapy drugs and\/or epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) can improve the outcome of these patients. Here, we report a stage IIIA patient who developed multiple brain metastases one year after operation. Oral gefitinib with concurrent WBRT were given as first-line therapy. Complete response and a 50-month progression-free survival (PFS) were obtained. Double dosage of gefitinib (500 mg per day) together with pemetrexed were given as the second-line therapy after the patient developed new brain lesions and leptomeningeal metastasis during the maintenance therapy of gefitinib. The PFS for the second-line therapy was six months. In total, the patient obtained an overall survival of 59 months since the first diagnosis of brain metastases. Mutational analysis showed a 15-nucleotide deletion and a missense mutation in exon 19 of the EGFR gene, and a missense mutation at codon 12 of the K-ras gene. These underlying genetic changes might partially explain the long-term survival of this patient after brain metastases when treated with concurrent or sequential therapies of EGFR-TKI, radiotherapy and chemotherapy.<\/jats:p>","DOI":"10.1186\/1477-7819-10-235","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T17:14:10Z","timestamp":1352308450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib"],"prefix":"10.1186","volume":"10","author":[{"given":"Ying","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Modan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,7]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1023\/A:1005775029983","volume":"36","author":"CY Hsiung","year":"1998","unstructured":"Hsiung CY, Leung SW, Wang CJ, Lo SK, Chen HC, Sun LM, Fang FM: The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy. J Neurooncol. 1998, 36: 71-77. 10.1023\/A:1005775029983.","journal-title":"J Neurooncol"},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.lungcan.2009.12.001","volume":"69","author":"V Surmont","year":"2010","unstructured":"Surmont V, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R, Gras J, Van Wijk A, Phernambucq EC, van Meerbeeck JP, Senan S, Kraaij CJ, Chouaki N, Praag J, van Klaveren RJ: Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. Lung Cancer. 2010, 69: 302-306. 10.1016\/j.lungcan.2009.12.001.","journal-title":"Lung Cancer"},{"key":"1175_CR3","first-page":"207","volume":"14","author":"DY Kim","year":"2005","unstructured":"Kim DY, Lee KW, Yun T, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK: Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep. 2005, 14: 207-211.","journal-title":"Oncol Rep"},{"key":"1175_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2008.10.028","volume":"65","author":"S Ma","year":"2009","unstructured":"Ma S, Xu Y, Deng Q, Yu X: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009, 65: 198-203. 10.1016\/j.lungcan.2008.10.028.","journal-title":"Lung Cancer"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.lungcan.2009.03.019","volume":"65","author":"A Omlin","year":"2009","unstructured":"Omlin A, D\u2019Addario G, Gillessen S, Cerny T, von Hessling A, Fr\u00fch M: Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer. 2009, 65: 383-384. 10.1016\/j.lungcan.2009.03.019.","journal-title":"Lung Cancer"},{"key":"1175_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","volume":"68","author":"A Bearz","year":"2010","unstructured":"Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U: Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer. 2010, 68: 264-268. 10.1016\/j.lungcan.2009.06.018.","journal-title":"Lung Cancer"},{"key":"1175_CR7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","volume":"22","author":"F Barlesi","year":"2011","unstructured":"Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G: Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07\u201301). Ann Oncol. 2011, 22: 2466-2470. 10.1093\/annonc\/mdr003.","journal-title":"Ann Oncol"},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","volume":"25","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Fine RL: Increased permeability of the blood\u2013brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007, 25: 2306-2312. 10.1200\/JCO.2006.10.0677.","journal-title":"J Clin Oncol"},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0006-8993(97)01502-3","volume":"792","author":"K Matsukado","year":"1998","unstructured":"Matsukado K, Sugita M, Black KL: Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 1998, 792: 10-15. 10.1016\/S0006-8993(97)01502-3.","journal-title":"Brain Res"},{"key":"1175_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0169-5002(03)00189-2","volume":"41","author":"F Cappuzzo","year":"2003","unstructured":"Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crin\u00f2 L: Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003, 41: 227-231. 10.1016\/S0169-5002(03)00189-2.","journal-title":"Lung Cancer"},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","volume":"46","author":"K Hotta","year":"2004","unstructured":"Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A, Tanimoto M: Effect of gefitinib (\u2018Iressa\u2019, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004, 46: 255-261. 10.1016\/j.lungcan.2004.04.036.","journal-title":"Lung Cancer"},{"key":"1175_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2169\/internalmedicine.43.718","volume":"43","author":"A Ishida","year":"2004","unstructured":"Ishida A, Kanoh K, Nishisaka T, Miyazu Y, Iwamoto Y, Kohno N, Miyazawa T: Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases. Intern Med. 2004, 43: 718-720. 10.2169\/internalmedicine.43.718.","journal-title":"Intern Med"},{"key":"1175_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.lungcan.2007.03.011","volume":"57","author":"C Wu","year":"2007","unstructured":"Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007, 57: 359-364. 10.1016\/j.lungcan.2007.03.011.","journal-title":"Lung Cancer"},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2005.05.022","volume":"50","author":"MK Kim","year":"2005","unstructured":"Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS: Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer. 2005, 50: 265-269. 10.1016\/j.lungcan.2005.05.022.","journal-title":"Lung Cancer"},{"key":"1175_CR15","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","volume":"24","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, J\u00e4nne PA, Johnson BE: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006, 24: 4517-4520. 10.1200\/JCO.2006.06.6126.","journal-title":"J Clin Oncol"},{"key":"1175_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N, Miller VA, Lassman AB: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010, 99: 283-286. 10.1007\/s11060-010-0128-6.","journal-title":"J Neurooncol"},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jnci\/dji112","volume":"97","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 643-655. 10.1093\/jnci\/dji112.","journal-title":"J Natl Cancer Inst"},{"key":"1175_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005, 97: 339-346. 10.1093\/jnci\/dji055.","journal-title":"J Natl Cancer Inst"},{"key":"1175_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/JTO.0b013e3181cee47e","volume":"5","author":"M Takeda","year":"2010","unstructured":"Takeda M, Okamoto I, Fujita Y, Arao T, Ito H, Fukuoka M, Nishio K, Nakagawa K: De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol. 2010, 5: 399-400. 10.1097\/JTO.0b013e3181cee47e.","journal-title":"J Thorac Oncol"},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","volume":"9","author":"H Linardou","year":"2008","unstructured":"Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9: 962-972. 10.1016\/S1470-2045(08)70206-7.","journal-title":"Lancet Oncol"},{"key":"1175_CR21","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1200\/JCO.2009.27.4365","volume":"28","author":"PJ Roberts","year":"2010","unstructured":"Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol. 2010, 28: 4769-4777. 10.1200\/JCO.2009.27.4365.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-10-235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:14:31Z","timestamp":1630530871000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-10-235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-10-235","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,7]]},"assertion":[{"value":"29 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"235"}}